Cytokinetics, Incorporated

CYTKNASDAQHealthcare● Active

$67.90

$-3.58(-5.01%)

Market Cap$8.4B

P/E Ratio—

52W High$80.2

52W Low$31.52

Avg Volume2.4M

Open$72.00

Beta0.43

Free Cash Flow Financials Revenue

Cytokinetics, Incorporated (CYTK) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

CYTK · free cash flow · updated Jun 8, 2026

Core FCF metrics

CYTK · FCF · TTM · margin & CAGR

Free cash flow was −$534.8M for FY2025 (fiscal year ending 2025-12-31), down 33.8% year-over-year The FCF margin was -607.5%.

FY2025 Free Cash Flow−$534.8M▼ -33.8% YoY

Trailing 12M (TTM)−$548.9Mtrailing 4 quarters sum

FCF Margin-607.5%−$534.8M ÷ revenue

3-Year CAGRN/AN/A — contains negative FCF

5-Year CAGRN/AN/A — contains negative FCF

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 8, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

CYTK · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2025Latest−$510.0M(25M)−$534.8M▼ 33.8%-607.5%

FY2024−$395.9M(4M)−$399.8M▲ +3.8%—

FY2023−$414.3M(1M)−$415.7M▼ 33.7%—

FY2022−$299.5M(11M)−$310.9M▼ 62.4%-328.6%

FY2021−$142.5M(49M)−$191.4M▼ 8975.1%-271.8%

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

CYTK · P/FCF · FCF yield · FCF per share

Cytokinetics, Incorporated (CYTK) reported negative free cash flow of −$0.53B. FCF-based valuation ratios are not meaningful when FCF is negative.

FCF Yield (TTM)

N/A

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

N/A

TTM FCF ÷ Shares Outstanding

Price / FCF

N/A

Share Price ÷ FCF per Share

EV / FCF (TTM)

N/A

Enterprise Value basis

FCF-based valuation ratios are only meaningful when free cash flow is positive. Negative FCF indicates capital expenditures exceeded operating cash flow.

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2025 · 2025-12-31

Cash flow statement summary

CYTK · cash flow statement · operating / investing / financing

For FY2025, Cytokinetics, Incorporated generated −$510.0M in operating cash flow and spent 25M in capital expenditures, yielding −$534.8M in free cash flow.

Operating Activities

−$510.0M

Cash from core business operations

2025-12-31

Investing Activities

+$16.7M

CapEx, acquisitions & investments

2025-12-31

Financing Activities

+$524.5M

Buybacks, dividends & debt

2025-12-31

FCF FormulaOperating CF (−$510.0M) − |CapEx| (25M) = FCF (−$534.8M)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

CYTK vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

Cytokinetics, IncorporatedYOU

CYTK

−$534.8M-33.8%-607.5%

Loss

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

Cytokinetics, Incorporated (CYTK) reported free cash flow of −$534.8M for FY2025 (fiscal year ending 2025-12-31), down 33.8% year-over-year. The FCF margin was -607.5%.

Based on available data, Cytokinetics, Incorporated has maintained positive free cash flow for at least 2 fiscal year(s). FCF peaked at $35.4M in FY2016.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

CYTK free cash flow · 8 questions

Cytokinetics, Incorporated free cash flow was −$534.8M for FY2025, down 33.8% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at −$548.9M.

CYTK free cash flowCYTK FCFCYTK FCF 2025CYTK free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · Cytokinetics, Incorporated · Cytokinetics, Incorporated SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 8, 2026